JB Chemicals & Pharmaceuticals Q2 Results Live : JB Chemicals & Pharmaceuticals has announced its Q2 results for the fiscal year, revealing a notable increase in profits and revenue. The company declared its financial performance on November 6, 2024, showing a year-over-year revenue growth of 13.48% and a profit increase of 15.92%. However, compared to the previous quarter, the revenue saw a slight decline of 0.38%, and profit decreased by 1.28%.
The company’s selling, general, and administrative expenses increased by 2.19% quarter-over-quarter and rose significantly by 15.03% year-over-year. This uptick in expenses has contributed to a decrease in operating income, which was down by 4.57% compared to the last quarter, although it still reflects an increase of 8.17% year-over-year.
Earnings per share (EPS) for the quarter stood at ₹11, marking a year-over-year increase of 15.3%. Despite the mixed results, JB Chemicals & Pharmaceuticals has shown resilience, with a -0.1% return in the last week, a 4.57% return over the past six months, and a robust 15.76% year-to-date return.
Currently, JB Chemicals & Pharmaceuticals boasts a market capitalization of ₹29,209.98 crore, with a 52-week high of ₹2030 and a low of ₹1371. The stock’s performance has attracted attention from analysts, with 1 analyst giving a Strong Sell rating, 2 analysts recommending a Hold, 2 advising a Buy, and 6 providing a Strong Buy rating.
As of November 7, 2024, the consensus recommendation among analysts is to Buy, indicating a positive outlook for the company’s future performance.
JB Chemicals & Pharmaceuticals Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1000.62 | 1004.4 | -0.38% | 881.74 | +13.48% |
| Selling/ General/ Admin Expenses Total | 170.57 | 166.91 | +2.19% | 148.28 | +15.03% |
| Depreciation/ Amortization | 41.88 | 40.78 | +2.7% | 32.17 | +30.18% |
| Total Operating Expense | 771.98 | 764.81 | +0.94% | 670.37 | +15.16% |
| Operating Income | 228.64 | 239.59 | -4.57% | 211.37 | +8.17% |
| Net Income Before Taxes | 236.53 | 239.84 | -1.38% | 208.66 | +13.36% |
| Net Income | 174.57 | 176.83 | -1.28% | 150.59 | +15.92% |
| Diluted Normalized EPS | 11 | 11.16 | -1.43% | 9.54 | +15.3% |
